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ABSTRACT 
EFFICACY OF 180 VS. 360 DEGREES OF SELECTIVE LASER TRABECULOPLASTY ON LOWERING 
INTRAOCULAR PRESSURE. Robert H. McGlynn (Sponsored by M. Bruce Shields). Department of 
Ophthalmology, Yale University, School of Medicine, New Haven, CT 
The purpose of this study was to determine if the application of 360° of selective laser trabeculoplasty 
(SLT) to the trabecular meshwork (TM) is more effective than 180° in the lowering of intraocular pressure (IOP) 
in glaucoma.   This issue was addressed in the form of a retrospective chart review of patients treated 
consecutively with SLT for primary open angle glaucoma, pseudoexfoliation glaucoma or ocular hypertension.  
Patients were treated with either 180° of SLT by Dr. Wand or 360° by Dr. Martone using a 532nm, Q-switched, 
frequency doubled Nd:Yag laser.  Only the initial treatment with SLT of a given eye was analyzed.  There were 
108 patients per group.  Patient age, type of glaucoma, history of previous argon laser trabeculoplasty (ALT), 
number of medications, lens status and visual acuity pre-and post-treatment and the number and power of laser 
spots were compared between the treatment groups.  The mean IOP from three consecutive visits prior to 
treatment was compared with post-operative IOPs measured at 1 hour, 6 weeks, and 3 months.  Patients were 
classified as responders if the three month postoperative IOP was reduced by more than or equal to 3 mmHg 
compared to baseline.   
At three months post-op the 360° group had a response rate of 60% and a mean IOP drop of 3.6 
mmHg (17.8%).  The 180° group had a response rate of 29% with a mean IOP drop of 1.5 mmHg (7.5%).  The 
number of pre- and post-treatment medications, eye treated, gender, phakic status, number of spots delivered and 
pre-op IOP were equivalent for the two study groups.  The 180° group subjects had more overall energy delivered 
during treatment and had had previous ALT more frequently than the 360° group.  The 180° group also was 
significantly older and was less likely to have non-open angle glaucoma. 
This study suggests that with a 2.1 mmHg greater drop in IOP and 31% greater response rate at three 
months post-op 360 degrees of SLT is more effective in lowering intraocular pressure than 180 degrees.   
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INTRODUCTION 
Argon Laser Trabeculoplasty 
Histopathology and Mechanism 
Argon Laser Trabeculoplasty (ALT) was shown by Wise and Witter to be an effective 
treatment for lowering intraocular pressure (IOP) open angle glaucoma (OAG) in 1979 (1).  
ALT employs the application of argon laser burns to the trabecular meshwork (TM) in the 
anterior chamber angle of the eye.  These burns cause coagulative damage to uveoscleral 
meshwork, disruption of the trabecular beams and heat-induced damaged to surrounding 
collagen fibers (2).  The precise mechanism of action is unknown but one theory, known as 
the mechanical theory, is that the thermal energy causes coagulation and, hence, contraction of 
the areas of application.  This contraction causes shrinkage of the inner TM ring applying 
traction on the intervening meshwork and Schlemm’s canal.  The traction causes separation of 
the trabecular sheets and prevents the collapse of Schlemm’s canal, therefore facilitating 
outflow of aqueous humor and lowering IOP.  Similar histopathological changes in the 
ultrastructure of the TM as those produced by ALT have been documented after the 
application of 1064 nm neodymium:yittrium-aluminum-garnet (Nd:YAG) and diode lasers 
(3,4).  Another theory, the cellular theory, postulates that ALT causes increases in both cell 
division (5) and phagocytic activity (6) in the trabecular endothelial cells.  This is thought to 
cause clearing of debris from the trabecular meshwork as well as stimulate growth of healthy 
trabecular tissue, thus facilitating aqueous outflow.  Furthermore, ALT has been shown to 
induce expression and secretion of IL-1 and TNFalpha (7).  This in turn leads to increased 
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expression of stromelysin in trabecular cells which plays an important role in remodeling of 
the trabecular extracellular matrix and increasing aqueous outflow.   
 
Clinical Efficacy 
ALT was shown in the Glaucoma Laser Trial (GLT) to produce lower IOP, better 
visual acuity and better optic disc status in treated eyes when compared to eyes treated 
medically when employed as the initial treatment of glaucoma (8).  In the seven year follow-up 
of the GLT study initial treatment with ALT was again found to be as, if not more, efficacious 
than initial medical treatment of glaucoma with an average IOP reduction of 7-10 mmHg (9).  
That IOP reduction was 1.2 mmHg greater than that demonstrated by the primary medical 
treatment group.   Despite these findings ALT is most commonly used after medical options 
have been explored without resulting in adequate IOP control in hopes of postponing or 
eliminating the need for filtering or cyclodestructive surgery.  While ALT has proved to be an 
effective treatment, long term failure of IOP control is common.  One study reported that 
ALT controlled IOP in one-third of patients after a five year follow-up (10).  Defining success 
of treatment as a 3 mmHg decrease in IOP or more, another study found that 21% of subjects 
treated with ALT were successes after five years (11).  The failure of IOP control is 
hypothesized to be due to destruction of the uveoscleral meshwork from thermal damage and 
membrane formation from migrating endothelial cells over the TM in between laser 
applications (12, 13).  In addition to long-term treatment failure, ALT can also produce 
significant side effects in treated individuals.  These side effects include post-op IOP spikes, 
iritis and peripheral anterior synechiae (14, 15).   The amount of energy delivered during 
treatment correlated with the incidence of these side-effects but did not effect the long-term 
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reduction in IOP (16, 17).  Seeking to reduce the frequency of these side-effects led 
investigators to attempt to lower the total amount of energy delivered to the TM without 
losing efficacy of the treatment. 
 
Selective Laser Trabeculoplasty 
Selective Thermolysis 
Selective Laser Trabeculoplasty (SLT) is a newer technique that uses an Nd:YAG laser 
to selectively target pigmented trabecular cells without causing widespread thermal damage to 
the trabecular meshwork.  This technique was developed by Latina and Park in 1995 by 
applying lasers pulses of various frequencies, duration and power to a mixed cell culture of 
pigmented and non-pigmented TM cells (18).    They found that with lasers capable of pulses 
in the sub-microsecond range it was possible to define a range of energy pulses in which 
pigmented TM cells could be selectively damaged and killed while leaving adjacent non-
pigmented TM cells unharmed.  The theory upon which SLT is based and which makes this 
selective killing possible is called selective thermolysis.  The brevity of the laser pulses is critical 
to produce selective thermolysis because in order to specifically target pigmented TM 
endothelial cells the pulse duration must be shorter than the thermal relaxation time of 
melanin.  Thermal relaxation is the time required for a chromophore to convert 
electromagnetic energy into thermal energy.  At pulse durations less than the thermal 
relaxation time, energy is deposited in the melanin granules faster than it can diffuse.  The 
thermal energy is therefore limited to the pigmented granules in the TM endothelial cells with 
very little dissipated to surrounding structures, limiting their damage.   
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The thermal relaxation time of melanin is approximately 1 μsec explaining why pulse 
durations below this threshold allowed for selective targeting.  When cultures irradiated using a 
low energy, q-switched, frequency doubled Nd:YAG laser emitting at 523 nm in 10 nsec pulses 
were examined the damage was strictly limited to lysosomes containing pigment granules.  This 
was seen as fractured melanin granules and ruptured lysosomal membranes on transmission 
electron microscopy.  At pulses that approached this threshold, such as the 1 μsec pulses of 
the pulsed dye laser used in this study, damage was seen to subcellular organelles surrounding 
the pigment granules in addition to the granules themselves.  This gave evidence of the 
importance of thermal diffusion in the production of collateral damage to surrounding 
structures.  At the light microscopy level, the damage induced by these two lasers was so subtle 
that it was difficult for the investigators to distinguish irradiated areas by phase contrast 
microscopy.  Using stains to identify compromised cells they found non-pigmented cells 
remained viable even when all of their adjacent pigmented cells had been killed.  Cultures 
irradiated with longer pulse durations at energies above the threshold that caused cell damage 
showed complete vaporization of both pigmented and non-pigmented cells at the burn sites.   
The q-switched, frequency doubled Nd:YAG laser application delivers about 0.6 – 1.0 
mJ per pulse which is 1% of what traditional ALT delivers at 60-100 mJ per pulse.  SLT is able 
to be applied over a much larger area because spatial targeting is unnecessary.  SLT is usually 
applied with a spot size of 400 μm versus the 50 μm spot size in ALT. Coupling the lower 
amount of energy delivered in SLT with a larger spot size over which this energy is applied 
leads to a far lower fluency (energy/area) in SLT when compared with ALT.  Due to the low 
fluency required together with the approximately 1mm tissue penetration and relative 
transparency of collagen in the trabecular beams to 523 nm light, it was hypothesized that the 
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results found on the two dimensional cell cultures could be applied to the three dimensional 
trabecular meshwork with similar selectivity. 
 
Histopathology 
Microscopic studies have subsequently shown the selectivity of SLT when applied to 
human eyes.  Scanning electron microscopy (SEM) performed on the TM after application of 
ALT showed crater formation with evidence of coagulative damage at the base and edges (2).  
This was seen in the form of whitening and bleb formation.  There was also disruption of the 
collagen scaffolding and trabecular beams with debris from these structures in the adjacent 
intratrabecular spaces.  SEM on SLT treated specimens, on the other hand, showed minimal 
mechanical disruption of the collagen scaffolding and trabecular beams with no evidence of 
crater formation or coagulative damage.  Transmission electron microscopy (TEM) on ALT 
specimens showed similar disruption of trabecular beams and collagen scaffolding immediately 
surrounding the laser lesions.  Additionally, trabecular endothelial cells were found to be 
disrupted with many of them appearing to be detached from the trabecular beams.  The 
pigment granules within these cells were rounded and intact.  SLT specimens examined with 
TEM showed no disruption of the TM which was lined with a continuous layer of trabecular 
endothelial cells.  In contrast to the ALT treated specimens many of the intracytoplasmic 
pigment granules in the SLT treated specimens were cracked and fragmented as Latina and 
Park (18) found in cell culture.  This is precisely where SLT is designed to interact.  Many of 
these endothelial cells were also vacuolated.  The Kramer et al. study (2) study involved ALT 
using the standard energy delivery levels of 60 – 100 mJ/pulse.  A more recent study examined 
the effect of lower energy ALT (46 mJ/pulse) versus standard SLT application to the TM of 
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eyes one to five days prior to enucleation for malignant melanoma of the choroid (19).   This 
study found that both treatments caused disruption of the trabecular beams and desquamation 
of endothelial cells but that the extent of this damage was less after SLT.  They also found that 
long-spacing collagen was better preserved after SLT.   
 
Mechanism of Action 
The lack of coagulative damage induced by ALT suggests that any IOP reduction 
caused by SLT is due to the selective killing of pigmented trabecular meshwork cells and the 
biologic response that ensues.  Multiple biologic reactions have been documented and all of 
them can be at least partially attributed to the induced expression of various cytokines after 
SLT.   
 
Cytokine Production and Endothelial Cell Permeability  
As with ALT, SLT has been shown to increase expression of IL-1 and TNF-alpha with 
the addition of IL-8 (20).  These cytokines are important in the recruitment of macrophages 
which may help to clear debris from the TM and facilitate aqueous outflow.  A study by 
Alvarado et al. (20) found that SLT applied to trabecular meshwork cells in culture produces 
increased levels of these cytokines in the culture medium.   When endothelial cells from the 
TM and Schlemm’s canal were incubated with this culture medium it was found that it 
significantly altered their genetic expression.  The increase in cytokine activity and altered 
expression of genes occurs simultaneously with an increased rate of conductivity of aqueous 
humor across monolayers of these two cell types.  This increased conductivity is also 
reproducible by administering exogenous IL-1 alpha and beta, TNF-alpha and IL-8 to these 
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cellular monolayers.  This is an important finding because the endothelial cells of Schlemm’s 
canal form the last barrier of the outflow tract and exert important control over how much 
aqueous humor leaves the eye and enters the venous circulation.  If SLT produces the same 
four-fold increase in conductivity in Schlemm’s canal endothelial cells in vivo that it produces 
in vitro it could explain much of the IOP reduction seen clinically.   
 
Extracellular Matrix Remodeling 
The TM extra-cellular matrix has been shown to be both increased and modified in 
primary open angle glaucoma (POAG) (21, 22).  This is thought to be another pivotal factor in 
the outflow resistance and elevated IOP in this condition.  The normal turnover of the TM 
extra-cellular matrix is partially governed by the activity of metalloproteinases (MMPs) (23, 24).  
The activity of MMPs, in turn, is increased by the cytokines IL-1 and TNF-alpha (25, 26, 27).  
The ratio of MMP concentration to the concentration of their inhibitors’ is also increased by 
these cytokines.  These inhibitors are called tissue inhibitors of metalloproteinases, or TIMPs.  
MMP-2 is the predominant gelatinase in the aqueous humor and its inhibitor, TIMP-2, is up 
regulated in POAG (28).  This imbalanced ratio of MMP-2 to TIMP-2 is thought to be 
responsible for the decreased collagenase activity of aqueous humor from POAG eyes in vitro 
(29).  The increased expression of cytokines after SLT could be influencing the ratio between 
these two factors and inducing remodeling of the extracellular matrix in the TM.  This finding 
is similar to the finding of increased expression of stromalysin, another MMP, due to increased 
IL-1 and TNF-alpha activity after ALT (27).   
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Endothelial Cell Repopulation 
Another one of the main factors that is thought to contribute to the etiology of POAG 
is the relative dearth of endothelial cells in the TM when compared to healthy controls.  The 
endothelial cells in the TM and Schlemm’s canal undergo mechanical deformation due to 
stretching when IOP is elevated (30).  This mechanical stretching has been shown to induce 
various changes in signal transduction, genetic expression and permeability in the anterior 
segment of the human eye (31, 32).  Among the up regulated genes are PIP 5K1C, VIP, 
tropomodulin, and MMP2 which are known to influence outflow resistance.   A similar 
increase in MMP-2 as well as a decrease in TIMP-2 in TM endothelial cells due to mechanical 
stretch have been found in other studies (33).  This increased expression of MMP-2 was 
shown to correlate with the ability of eyes challenged with increased flow rates to restore IOP 
to normal levels after a couple of days (34).  This effect was hypothesized to be a result of 
pruning of the TM extracellular matrix and subsequent reduction in outflow resistance.  The 
decreased cellularity of the TM in POAG when compared to age matched normal controls 
(35) may lead to increased IOP due to an inability of the present cell population to generate 
equivalent levels of these factors in response to a given IOP as would be produced by a 
normally populated TM.  This decreased cellularity of TM endothelial cells may also contribute 
to elevated IOP by not being able to produce sufficient concentrations of cytokines to 
adequately alter the permeability of the Schlemm’s canal’s endothelial cells.  The importance of 
this is that laser treatments have been shown to increase cell division in the TM (5).  This is 
likely to be at least partially due to the ability of cytokines to act as growth factors for TM 
endothelial cells.  SLT, by inducing cytokine expression, may be triggering a repopulation of 
the TM endothelial cells and therefore restoring the ability of this cell population to adequately 
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respond to increases in IOP.  The new population of TM cells could then secrete factors 
important in the regulation of the permeability of Schlemm’s canal endothelial cells and in the 
proper turnover in the TM extracellular matrix.  
There is one more piece of evidence that supports the importance of the biological 
response induced by SLT in lowering IOP.  This evidence comes from a study that found that 
untreated eyes contra lateral to SLT treated eyes exhibit a statistically significant pressure 
reduction (36).  This study found a 9.7% IOP reduction in these untreated eyes at 6 months.  
A mechanical mode of action is ruled out in the contra lateral eye as the laser was not applied 
there.  This suggests that the inflammatory cascade induced in the treated eye has some 
crossover effect in the untreated eye. 
In summary, there is strong evidence that SLT is inducing biological responses in the 
TM that are responsible for IOP reduction.  These mechanisms are the increased expression 
of cytokines, increased permeability of the endothelial cells in the TM and Schlemm’s canal, 
remodeling of the extracellular matrix of the TM and repopulation of TM endothelial cells.  All 
of these mechanisms influence each other and the induction of cytokine expression plays a 
potential role in modulating all of them. 
 
Clinical Efficacy 
Clinical trials thus far conducted have shown reasonable response rates, effective IOP 
reduction and minimal side effects.  The first study to look at the clinical applicability of this 
procedure was published in 1998 (36).   This study included a total of 53 eyes with 
uncontrolled open-angle glaucoma (OAG) treated with 180° degrees of SLT followed for 26 
weeks.  They found that 70% of the treated subjects had a reduction of IOP of greater than 3 
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mmHg with an average drop of 4.6 mmHg (18.7%) after 26 weeks.  The magnitude of this 
reduction was uninfluenced by previous treatment with ALT.  This demonstrated that 
effective, clinically significant IOP reduction could be accomplished without inflicting 
coagulative damage to the trabecular meshwork.  Interestingly, this study also found that there 
was a statistically significant, albeit less extensive, 9% reduction in the IOP of the fellow 
untreated eyes in these subjects. Subsequently there have been many other studies published 
addressing the clinical efficacy of SLT.   These results are summarized in Table 1.  Overall, the 
response rate to SLT was 63.1% with a range from 14-88% at a mean follow-up time of 19.4 
months.  The mean decrease in IOP was 6.18 mmHg (2.1-10.6) with a percentage decrease of 
26.0% (11.9-39.9).  When only the studies that reported follow-up periods of longer than one 
year are included in these figures the mean response rate was 60.2% with a mean IOP drop of 
5.7 mmHg (2.1-8.6)  reflecting a 24.0% drop (11.9-35.1).  These are significant responses and 
the majority are either similar to or better than outcomes reported for ALT (9, 10, 11).  
 
Table 1 
Summary of studies reporting efficacy of SLT 
 Sample Baseline 
IOP 
(mmHg) 
Follow-up Response Rate IOP Reduction 
(mmHg) 
Latina et al. 
(36) 
50 POAG 
3 PG 
24.6 26 weeks 70% 4.6 (18.7%) 
Lanzetta et al. 
(37) 
8 POAG 26.6  6 weeks  10.6 (39.9%) 
Kim et al. (38) 16 POAG 24.4  1 year  4.9 (20.2%) 
Gracner (39) 50 POAG 22.5  6 months 88% 5.1 (22.5%) 
Gracner (40) 10 CG 
10 POAG 
23.6  
22.8  
12 months 
13.5 months 
64% 
78% 
7.4 (31.4) 
8.0 (35.1%) 
 
 
Melamed et al. 
(41) 
45 POAG 
     (primary Tx) 
25.5  18 months  7.7 (30%) 
Cvenkel (42) 44 POAG 25.6 1 year 62% 4.7 (18.6%) 
Lai et al. (43) 29 POAG/OHT 26.8 5 years  8.6 (32%) 
Best et al. (44) 269 POAG/LTG/OHT 22.7 2 years  2.7 (12.1%) 
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Table 1 continued 
Kano et al. 
(45) 
67 POAG 22.4 6 months 68.7% at 1 mo. 4.4 ( 19.6%) 
Hodge et al. 
(46) 
72 POAG/PXG/PG 23.8 1 year 59.7% 5.8 (24.4%) 
Kajiya et al. 
(47) 
17 POAG 22.8 6 months  6.7 (29.4%) 
Jindra (48) 283 POAG 
      (primary Tx) 
43 POAG 
      (repeat Tx) 
21.1 
 
23.7 
4.8 months 
 
3.5 months 
 7.4 (35%) 
 
8.2 (35%) 
Song et al. (58) 94 
POAG/PXG/PG/LTG
17.6 
68.7+ 
14.5 months 14% 2.1 (11.9%) 
Table 1.  Summary of studies reporting efficacy of SLT.  Abbreviations: SLT, selective laser 
trabeculoplasty; IOP, intraocular pressure; POAG, primary open angle glaucoma; CG, capsular 
glaucoma; OHT, ocular hypertension; LTG, low-tension glaucoma; PXG, pseudoexfoliation glaucoma; 
PG, pigmentary glaucoma. 
   
SLT vs. ALT 
Clinical trials that have compared ALT to SLT have also shown that the two 
treatments have similar efficacy.  A study comparing 154 patients treated with ALT to 41 
patients treated with SLT, all on maximal medical therapy, found that there was no significant 
difference in success of treatment at an average follow-up time of 34.4 months (11).  This 
equivalence was found two separate criteria for success: one was and IOP reduction of greater 
than 20% of baseline IOP (P=0.12) and the second was an IOP reduction of greater than 3 
mmHg (p=0.20).  There was no significant difference in the percentage reductions in IOP with 
27.1% and 23.5% decreases in the SLT and ALT groups respectively (P=0.75).  Other studies 
comparing SLT to ALT are summarized in table 2.  Briefly, over an average follow-up period 
of 5.6 months these three studies reported an average IOP reduction of 4.8 mmHg (2.85-6.9) 
for SLT and 5.0 mmHg (2.63-6.6) for ALT.  This corresponded to percentage reductions of 
20.9% (13.4-29.2) for SLT and 22.0% (13.0-29.2) for ALT.  None of the IOP reductions 
differed significantly in any of the three studies.  This establishes that SLT is a viable treatment 
alternative to ALT.  In fact, it may offer some advantages such as a decreased incidence of 
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complications and a potential for repeatability that make it a more attractive treatment 
option when compared to ALT.  These issues will be discussed in greater detail below. 
 
Table 2 
Summary of studies comparing efficacy of SLT vs. ALT 
 SLT Sample ALT Sample Follow-up SLT IOP 
Reduction  
ALT IOP 
Reduction  
P-Value 
Martinez de 
la Casa et al. 
(49) 
20 POAG 20 POAG 6 months 5.4 mmHg 
(22.2%) 
4.6 mmHg 
(19.5%) 
0.81 
Damji et al. 
(50) 
18 POAG 18 POAG 6 months 5.0 mmHg 
(21.9%) 
4.8 mmHg 
(21.3%) 
0.97 
Popiela et al. 
(51) 
27 POAG 27 POAG 3 months 2.85 mmHg 
(13.4%) 
2.63 mmHg 
(13.0%) 
0.84 
Pirnazar et al. 
(52) 
30 POAG 27 POAG 12 months 6.9 mmHg 
(29.2%) 
6.6 mmHg 
(29.2%) 
0.86 
Tabak et al. 
(53) 
22 patients 17 patients 4 weeks 3.84 mmHg 
(17.7%) 
6.5 mmHg 
(26.8%) 
Not 
significant 
Table 2.  Summary of studies comparing efficacy of SLT vs. ALT.  Abbreviations: SLT, selective laser 
trabeculoplasty; ALT, argon laser trabeculoplasty; IOP, intraocular pressure; POAG, primary open 
angle glaucoma. 
 
SLT After ALT 
Due to the fact that SLT does not cause coagulative damage to the TM, it offers the 
possibility of benefiting patients who have failed previous ALT.  SLT can be applied without 
causing further scarring and potential outflow obstruction as is thought to be a possible 
problem with repeat ALT treatments.  A study conducted examining the effect of repeat ALT 
treatments on 40 eyes of 37 patients found a greater than 3 mmHg drop in IOP response rate 
of 32% (54).  At 1.75 years 14% of these patients continued to have successful control of IOP.  
This study concluded that although it is a safe option to repeat ALT, the likelihood of success 
is low.   
A study that addressed the question of the relative efficacy of repeat ALT treatments 
and SLT after previous ALT found that there was not significant difference between the two 
  
13
at the 5 year follow-up (11).  They found that there was no difference in the response rates 
when success was defined as a reduction of IOP greater than 3 mmHg (P=0.35) or greater 
than 20% (P=0.21).  It should be noted that 6 patients (14.6%) in the SLT group and 16 
patients (10.4%) in the ALT group had previously received 180 degrees of ALT. These 22 
patients were included in the no prior treatment groups during analysis.  This was done with 
the rationale that the treatment was a primary treatment because the surgeon treated the 
previously untreated 180 degrees of the TM.   In the other studies mentioned below these 
patients would have been included in the repeat treatment groups.  Differing from these 
findings, Damji et al. found that patients with previous failed ALT had a greater reduction in 
IOP with SLT (6.8 mmHg, 29.8%) than with repeat ALT (3.6 mmHg, 16.0%) (P= 0.01) after 6 
months (50).  
Another study that compared pressure reduction and response rates of SLT either as 
the primary laser treatment or after previous ALT found that there was no difference in IOP 
reduction in these two groups (36).  They reported 5.8 mmHg (23.5%) and 6.0 mmHg (24.2%) 
reductions in IOP at 26 weeks in the primary SLT and previous ALT groups, respectively.  
Both groups had a 3 mmHg IOP reduction response rate of 70%.  Similarly, Chen et al. that 
IOP reduction is independent of previous ALT treatments (55).   
 
Repeat SLT Treatments 
SLT has been shown to be as effective as ALT with less histological damage to the 
trabecular meshwork.  Additionally, the efficacy of SLT has been demonstrated in patients 
with previous ALT.  These two facts have lead to the promise of SLT being a repeatable 
treatment.  Repeat ALT is not favored due to the permanent changes it causes on the first 
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application and the mixed findings on its long term efficacy.  There is not yet much data 
supporting the clinical repeatability of SLT.  One study found that response rates on repeat 
SLT always exceeded 50%, in some cases by a considerable amount (56).  This study was 
conducted on a mixed group of glaucoma patients with a mean time of 12 to 15 months 
between SLT treatments.  In a small sample of patients that had received a third SLT 
treatment they found a 100% response rate with an average pressure reduction of 10.8 mmHg.  
They also found that the degree of pressure reduction and 3 mmHg IOP reduction response 
rate was positively correlated with having a baseline IOP of greater than 21 mmHg.  Another 
study compared 283 primary to 43 repeat SLT treatments and found that there was a 35% 
reduction in IOP in both groups (48).  All of these studies concur in their findings that, when 
repeated, SLT is effectively lowers IOP.   
 
SLT as Initial Therapy 
The Glaucoma Laser Trial Follow-up Study established ALT as a viable first line 
treatment option for POAG.  Despite this it continues to be employed after medical therapy 
has failed to control IOP in order to avoid the need for incisional pressure lowering surgery.  
Given the equivalent efficacy of SLT and ALT, it follows that SLT may be viable option for 
primary treatment of POAG as well.  In fact, there have been studies that support this 
hypothesis.  One study examined the response of 45 eyes with either POAG or ocular 
hypertension with a mean baseline IOP of 25.5 mmHg to primary treatment with SLT (41).  
At 18 months follow-up the mean drop in IOP was 7.7 mmHg (30%) with 43 of the 45 eyes 
responding with a greater than 20% reduction. Forty of the eyes had an IOP reduction of 
greater than 5 mmHg.  Another study compared 283 primary to 43 repeat SLT treatments and 
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found that there was a 35% reduction in IOP in both groups.  The initial treatment group 
had and IOP reduction of 7.4 mmHg from 21.1 to 13.7 mmHg.  The repeat group had a drop 
of 8.2 mmHg from 23.7 to 15.5 mmHg.  One additional study on 29 newly diagnosed patients 
randomized one eye of each patient to receive SLT and the other medical treatment (43).  The 
baseline IOPs were 26.8 and 26.2 mmHg in the SLT and medication groups respectively 
(p=0.62).  At the end of the five year follow-up the mean pressure drops were 8.6 (32.1%) and 
8.7 (33.2%), respectively (P=0.95).  They also had similar failure rates of therapy as defined as 
an IOP of greater than 21 mmHg at five years of 17.2% and 27.6%, respectively (P=0.53).  
Eight of the SLT eyes (27.6%) required medications to keep their IOP below this threshold 
but the SLT group required less medications at the five year follow-up (0.46-0.55) compared to 
the medications group (1.45-1.63) (P<0.001).  In summary, these studies suggest that as with 
ALT, SLT is an effective initial treatment for POAG. 
 
Adverse Effects 
SLT administers 1% of the energy delivered by ALT.  This most likely accounts for its 
relatively lower complication rate than ALT.  In the Glaucoma Laser Treatment Follow-up 
Study (9) 34% of subjects had an IOP rise more than 5 mmHg after treatment.  Following 
SLT, two studies reported incidence of IOP rises greater than 5 mmHg at 25% (41) and 11% 
(36).  Martinez-de-la-Casa et al. found that the degree of IOP elevation immediately following 
SLT was lower than that occurring after ALT, although this difference was not significantly 
different (49).  This same study compared the anterior chamber reaction after SLT and ALT.  
At 1 hour after treatment the SLT group had significantly less flare than the ALT group using 
a laser flare meter (13.3 vs. 20.7 photons/ms, P=0.003).  Alternatively, Damji et al. reported an 
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increased anterior chamber reaction after SLT when considering the number of cells 
observed (p<0.001) (50).  Another study reported that 83% of subjects had a mild to moderate 
anterior chamber reaction after SLT but that the usually decreased within 24 hours with no 
persistent cases of iritis (36).   
The incidence of pain after SLT has been reported at 15% of patients (36).  Another 
study described significantly less pain after SLT when compared to ALT (49).  The GLT group 
observed that 34% of patients receiving ALT had formation of peripheral anterior synechiae 
(PAS) (9).   These PAS did not have any effect on pressure control, number of medications 
needed or need for pressure reducing surgery.  In their original clinical study Latina et al. 
reported that there was no evidence of any PAS formation (36).  Other possible side effects 
are non-specific conjunctivitis and corneal edema but these are usually mild and transient 
occurrences.   
 
Variables Influencing Outcome of SLT 
ALT has previously been shown to produce a greater IOP decrease in eyes with a 
higher initial pressure (57).  Studies on SLT have thus far returned mixed results.  One study 
from Japan found that lower baseline IOP was predictive of SLT success (45).  Another study 
found precisely the opposite with a greater success rate in patients with higher baseline IOP 
(58).   An observational case study series found increased degree of TM pigmentation has been 
found to result in greater risk of complications, including post-op IOP spikes after SLT (59).  
Despite this increased rate of adverse effects another study found that TMs with greater 
degrees of pigment have significantly greater reductions in IOP at 7 month follow-up (55).  
This study also found that patients with pseudoexfoliation have an increased response to SLT.  
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The number of medications that a patient is on has also shown to have an effect on the 
outcome of ALT with the presence of fewer medications producing statistically significant 
better outcomes (60).  This has also been found with SLT (58).   
The type of medications an eye is treated with has also proved to be important in the 
outcome of SLT.  Eyes treated with prostaglandins have been reported to have a diminished 
response to SLT.  In one study there was a trend towards subjects on prostaglandins having a 
higher failure rate after SLT (58).  Another study found an increased percentage of patients on 
prostaglandins were not responsive to SLT (Bryce A. Ford MD, personal communication, 
2005).  They found that 76% of responders (41/54) were taking prostaglandins, compared to 
91% of non-responders (49/54) (p=0.039).  This decreased response rate may in part be due 
to the fact that both prostaglandins and SLT are thought to act on the aqueous outflow tract.  
PGs have been shown to induce increased expression of MMP-1,-2 and -3 both in vitro and in 
vivo (61).  In vivo, this induction corresponded with a decreased concentration of types I, III 
and IV collagen, which are some of the TM extracellular matrix substrates which the MMPs 
degrade.  As discussed above, SLT has been shown to act on this same pathway.  The 
population of MMPs may be depleted by prostaglandin treatment precluding SLT from acting 
on this pathway.  Another possibly redundant mechanism between these two treatments is that 
they both act by recruiting inflammatory cells.  Prostaglandins may be precluding the ability of 
SLT to cause a cellular response.  Despite the idea that steroids may interfere with the 
inflammatory cascade and thus diminish the efficacy of SLT, this has proved to be either 
unfounded (62) or possibly beneficial (63). 
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Degrees of TM Treated with SLT 
SLT has a lot of evidence supporting its use as a treatment for open angle glaucoma, 
possibly as a first line treatment.  This said it still remains a relatively new technique for which 
the optimal amount of power delivered and extent of the trabecular meshwork that should be 
treated still remains to be determined.  These issues have been addressed in previous studies 
although the question has not been sufficiently resolved.  With ALT the amount of energy 
delivered correlates with the incidence of post-op IOP spikes, iritis and peripheral anterior 
synechiae although this was not thought to influence the long-term reduction in IOP (14, 15, 
16).  A study comparing the degrees of the TM treated with ALT showed a greater success rate 
in eyes treated with 100 spots over 360 degrees (group 1, 26 eyes) when compared to eyes 
treated with 50 spots over 180 degrees (group 2, 20 eyes) (64).  The baseline IOP in group one 
was 35.9 mmHg and 36.3 mmHg in group 2.  Success was defined as a reduction of IOP to 
below 22 mmHg.  At 12 months group 1 and group 2 had success rates of 69% and 15%, 
respectively.   
Thus far there have been three studies examining the issue of the degree of the TM 
that should be treated with SLT.  One study by Chen et. al. found that 90 and 180 degrees of 
SLT had equivalent efficacy (55).  Both groups were composed of 32 eyes that were followed 
up for 7 months.  The baseline IOPs were 25.44 and 26.06 for the 90 and 180 degree groups, 
respectively.  The overall IOP reductions were 7.01 mmHg (27.6%) and 6.16 mmHg (23.6%), 
respectively (P=0.21).  There was no significant difference between the IOPs at 1, 4 or 7 
months.  There was also a similar rate of treatment failure with 15 of the 32 patients in the 90 
degree group requiring repeat SLT or trabeculectomy by the 7 month follow-up and 13 of the 
32 in the 180 degree group.   
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The second study by Nagar et. al. compared the relative efficacies of latanoprost and 
90, 180 and 360 degrees of SLT in 167 patients with either POAG or ocular hypertension (65).    
There were 39, 35, 49 and 44 patients in these groups, respectively.  At an average follow-up 
time of 10.3 months they found that the 360 degree group had success rates of 82% (greater 
than 20% reduction) and 59% (greater than 30% reduction).  The success rates in the 180 
degree group were 65% and 48%, as defined by these two criteria (P<0.1).  While these 
response rates trended towards being more efficacious with 360 degrees than 180 degrees they 
did not reach statistical significance.  Furthermore they found that 360 and 180 degree 
treatments had a greater response rate than 90 degrees (P<0.05), which was generally not 
effective.  Latanoprost had response rates of 90% and 78% which were significantly higher 
than 90 (p<0.001) and 180 (P<0.02) degrees but were statistically equivalent to those of 360 
degrees (P<0.5).   Adverse events including, IOP spikes, transient uveitis and ocular pain were 
more common in the 180 and 360 degree group compared to 90 degrees but only reached 
statistical significance in a couple of instances.  These instances were that ocular pain was more 
common (P>0.001) and mean IOP at 1 hour was higher (P<0.05) after 360 degrees than after 
90 degrees of SLT. 
The last study compared 19 eyes that received 180 degrees and 17 that received 360 
degrees of SLT (66).  The mean baseline IOP was 20.6 mmHg in the 180 degree group and 
21.7 mmHg in the 360 degree group.  The mean change in IOP was 1.7 mmHg (8.3%) in the 
180 degree group and 4.5 mmHg (20.7%) in the 360 degree group (p=0.15) at three months.  
Of these three studies, one showed no effect due to the extent of TM treated with 
SLT, another showed 360 degrees to be superior to 180 and 90 degrees and a third found a 
non-significant trend of 360 degrees being more efficacious than 180 degrees.  As discussed 
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above, ALT had a more robust IOP response when applied over 360 degrees of the TM 
than after 180 degrees.  SLT and ALT have been shown to have similar response rates and 
efficacy in many respects and these three studies suggest that they both have better efficacy 
when more of the TM is treated, although this is not yet established.  In order to address this 
question we conducted a retrospective chart review of 108 patients treated with 180 degrees 
versus 108 patients treated with 360 degrees of SLT. 
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MATERIALS AND METHODS 
Patient Selection 
A retrospective chart review of patients with primary open angle glaucoma, 
pseudoexfoliation glaucoma and glaucoma suspects treated with SLT was conducted.  Patients 
at the Hamden Eye Center were treated between January 22, 2004 and September 8, 2005 with 
360 degrees of SLT by Dr. James Martone.  Patients at the University of Connecticut were 
treated between September 5, 2002 and August 5, 2004 with 180 degrees of SLT by Dr. Martin 
Wand.  Patients were selected at the discretion of these physicians for SLT because they were 
felt to have IOPs above their goal pressures.  Therefore patients were included who had either 
failed to control IOP adequately on maximum medical therapy, opted for SLT treatment over 
medical treatment or were intolerant of medications.  After obtaining permission from Yale 
University School of Medicine Human Investigations Committee the charts of patients treated 
consecutively during these periods were reviewed and their eyes were included in the study if 
they met the inclusion criteria.  The inclusion criteria were: (1) eyes had to have POAG, 
pseudoexfoliation glaucoma or be glaucoma suspects, (2) the eye had to have undergone its 
first time treatment with SLT, (3) eyes had to have at least three pre- and post-operative IOP 
measurements with the last one being at least 3 months after treatment.   Exclusion criteria 
were: (1) prior treatment with SLT, (2) prior pressure lowering surgery including 
trabeculectomy, cyclodestructive therapy and peripheral iridotomies, (3) inadequate pre-
operative data, (4) inadequate post-operative follow-up.  Patients who had undergone prior 
ALT were included in this study.  Patient information including age, type of glaucoma, history 
of previous ALT, phakic status and pre- and postoperative visual acuity and number and type 
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of medications was collected.  In addition, which eye was treated, the number and power of 
laser spots, three consecutive pre-operative IOP measurements and two post-operative 
measurements at 6 weeks and three months were collected for both eyes.   
 
Operative Technique 
Dr. Martin Wand 
Patients were treated preoperatively with pilocarpine 2% and anesthetized with topical 
anesthetic.  SLT was applied with a Lumenis Selecta 532nm, Q-switched, frequency doubled 
Nd:Yag laser with a 3 nsec pulse duration using a slit lamp delivery system, a Latina goniolens 
and methylcellulose.  The TM was targeted using a helium-neon targeting beam.  An average 
of 103 spots were delivered over 180 degrees of the TM with a spot size of 400 μm.  This spot 
size was adequate to irradiate the entire anteroposterior width of the TM.   The energy level 
was initially set at 0.8 mJ and increased in 0.1 mJ increments until small bubbles appeared.  The 
rest of the TM was irradiated at this energy level.  The total amount of spots, the average 
energy per spot and the total amount of energy delivered were recorded. Post-operatively 
patients were treated with pilocarpine 2% and prednisolone.  They were then treated with a 
topical NSAID QID for 5 days while continuing on their prior pressure lowering medication 
regimen.  
 
Dr. James Martone 
Patients were treated preoperatively with pilocarpine 2% and apraclonidine 0.5%.  
They were anesthetized with topical properacaine 0.5%.  SLT was applied with a Lumenis 
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Selecta 532nm, Q-switched, frequency doubled Nd:Yag laser with a 3 nsec pulse duration 
using a slit lamp delivery system, a goniolens and methylcellulose.  The TM was targeted using 
a helium-neon targeting beam.  An average of 104 spots were delivered over 360 degrees of 
the TM with a spot size of 400 μm.  This spot size was adequate to irradiate the entire 
anteroposterior width of the TM.   The energy level was initially set at 0.8 mJ and increased in 
0.1 mJ increments until blanching or small bubbles were observed.  The energy was then 
backed off 0.1 mJ and the rest of the TM was irradiated at this energy level unless blanching or 
bubbling was again observed in which case the energy was lowered another 0.1mJ.  The total 
amount of spots, the average energy per spot and the total amount of energy delivered were 
recorded. Post-operatively patients were treated with diclofenac 0.1% ophthalmic solution 
QID for four days  while continuing on their prior pressure lowering medication regimen.  
 
Postoperative Follow-up 
Patients were seen by their respective treated physicians at 6 weeks and 3 months post-
operatively.  At these visits a slit lamp examination of the anterior segment and an IOP 
measurement using a Goldman applanation tonometer were performed.  At the three month 
follow up a follow-up visual acuity assessment was performed and the total number of 
medications was recorded.  Throughout the follow-up period patients’ antiglaucoma 
medications were adjusted as needed to control IOP. 
 
Success Criteria 
The primary outcome measure of this study was to compare the IOP reductions at 
three months after 180 and 360 degrees of SLT.  In addition to reporting mean IOP reduction 
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and percentage reduction of the two groups two sets of success criteria were defined that 
divided the treatments groups into responders and non-responders.  These two success criteria 
were 3 mmHg and 20% reductions of IOP from baseline values at three months..  Baseline 
IOP was determined by averaging the three consecutive IOP measurements immediately 
preceding the SLT administration.  These criteria were chosen because historically they have 
been the benchmarks by which success of laser trabeculoplasty treatments have been judged.   
 
Statistical Analysis 
All data was analyzed using SAS version 9.1 published by SAS Publishing Cary, NC.  
Visual acuity values were transformed into a logarithmic scale prior to analysis using the 
conversion chart described in table 3 (67). 
Table 3 
Snellen to Logarithmic Conversion Chart 
LogMAR Snellen LogMAR Snellen 
-0.30 10  0.70 100  
-0.20 12.5  0.76 114  
-0.10 16  0.80 125  
 0.00 20  0.88 150  
 0.10 25  0.90 160  
 0.18 30  1.00 200  
 0.20 32  1.10 250  
 0.30 40  1.18 300  
 0.40 50  1.20 320  
 0.48 60  1.30 400  
 0.50 63  1.60 800  
 0.54 70  2.00 2000  
 0.60 80  3.00 20000 
Table 3.   Chart used to convert Snellen chart measurements of visual acuity into a logarithmic scale. 
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RESULTS 
Patient Demographics 
A total of 216 eyes from 195 patients were included in the final analyses.  Table 4 
presents the baseline descriptive statistics of the patients in both treatment arms.  Patients in 
the 180° group were significantly younger than the 360° group with a mean age of 70.417 years 
versus 74.296 years (P=0.0176).  Distribution of gender and which eye was treated were 
equivalent between both groups (P=0.0525, P=0.2760, respectively). Glaucoma type 
composition of the two groups differed, with 99 patients in the 360° group and 106 patients in 
the 180° group having primary open angle glaucoma (P=0.0303).  The remaining patients in 
these two groups were composed of either pseudo-exfoliation glaucoma or were glaucoma 
suspects.  A statistically equivalent number of patients had previous cataract surgery and intra-
ocular lens placement in both groups with 28 and 32 patients (P=0.5434) in the 360° and 180° 
groups, respectively.  A total of 43 patients in the 180° group had received prior ALT 
application which was significantly more than the 18 patients in the 360° group (P=0.0002).  
Both groups had equivalent pre-operative visual acuity with means of 0.2615 and 0.2726 
(P=0.7242) in the 360° and 180° groups, respectively.  Both groups were on statistically 
equivalent number of medications pre-operatively (P=0.6148).  See figure 1 for graphic 
representation of number of medication administered to patients in both groups.  Of these 
medications the 180° group was on significantly more prostaglandins with 86 patients taking 
them pre-operatively compared with 59 patients in the 360° group (P<0.0001). 
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Table 4 
Summary of patient demographics 
Factor  360° 180° comments
    Age (years) 
 74.296 +/- 10.493 70.417 +/- 13.122 P=0.0176 
    
Male 37 (34.26%) 51 (47.22%) P=0.0525 
Gender 
Female 71 (65.74%) 57 (52.78%)  
    
OD 52 (48.1%) 60 (55.6%) P=0.2760 
Eye 
OS 56 (51.9%) 48 (44.4%)  
    
POAG 99 (91.7%) 106 (98.1%) P=0.0303 
PXG 7 (6.5%) 2 (1.9%)  
Glaucoma type 
GS 2 (1.9%) 0 (0%)  
    
Phakic 80 (74.07%) 76 (70.37%)  
Lens Status 
Psuedophakic 28 (25.93%) 32 (29.63%) P=0.5434 
    
No 88 (83.02%) 65 (60.19%)  
Previous ALT 
Yes 18 (16.98%) 43 (39.81%) P=0.0002 
    Pre-op Visual Acuity 
 0.2615 +/- 0.2413 0.2726 +/- 0.2172 P=0.7242 
    
0 12 (11.11%) 6 (5.56%)  
1 16 (14.81%) 19 (17.59%)  
2 29 (26.85%) 30 (27.78%)  
3 28 (25.93%) 26 (24.07%)  
No. of Meds, Pre-op 
≥4 23 (21.30%) 27 (25.00%) P=0.6148 
    
No 49 (45.37%) 21 (19.63%)  
Prostaglandin 
Treatment 
Yes 59 (54.63%) 86 (80.37%) P<0.0001 
Table 4.  Summary of patient demographics.  All values given +/- standard deviation.  Abbreviations: OD, right 
eye; OS, left eye; POAG, primary open angle glaucoma; PXG, pseudoexfoliation glaucoma; GS, glaucoma 
suspect; ALT, argon laser trabeculoplasty.  Visual acuity values were transformed into a logarithmic scale prior to 
analysis. 
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Figure 1.  Number of intraocular pressure lowering medications patients were taking prior to treatment 
with SLT in both 180 and 360 degree subgroups.  There was not a statistically significant difference in 
the number of medications the two treatment groups were receiving (P=0.6148). 
 
 
Post-operative results are summarized in table 5.  Both treatment arms received an 
equivalent number of SLT spots (P=0.7695).  The spots applied to the 180° group were 
significantly more powerful than the 360° group and therefore they received more overall 
power (107.38 mJ vs. 91.406 mJ, P<0.0001).  Post-operatively both groups had an equivalent 
decrease in the mean number of medications administered (-0.009 vs. -0.114, 360° vs. 180° 
respectively, P=0.2499) and were therefore still on comparable numbers of medications 
(P=0.3620).  Both groups also had a statistically equivalent reduction in visual acuity with a 
reduction of 0.0164 in the 360° group and 0.0069 in the 180° group (P=0.6455). 
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Table 5 
Results 
Factor  360° 180° Comments 
    No. of Spots 
Delivered  103.8 +/- 13.291 103.14 +/- 19.268 P=0.7695 
    Power Delivered 
(mJ)  91.406 +/- 10.634 107.38 +/- 31.311 P<0.0001 
    
0 16 (14.95%) 9 (8.57%)  
1 13 (12.15%) 19 (18.10%)  
2 28 (26.17%) 26 (24.76%)  
3 24 (22.43%) 30 (28.57%)  
No. of Meds, 
Post-op 
                            
                             
                           
                           
≥4 26 (24.30%) 21 (20.00%) P=0.3620 
    Mean No. of 
Med. Reduction 
 -0.009 +/- 0.5745 -0.114 +/- 0.7379 P=0.2499 
    Post-op VA 
Reduction 
 -0.0164 +/- 0.1748 -0.0069 +/- 0.124 P=0.6455 
    Pre-op IOP 
(mmHg)  19.299 +/- 4.1638 18.54 +/- 4.4992 P=0.1994 
    
1 hour 17.028 +/- 6.5245 19.093 +/- 5.9351 P=0.0158 
6 weeks 16.213 +/- 5.2025 16.278 +/- 5.3927 P=0.9285 
Post-op IOP 
(mmHg) 
3 months 15.747 +/- 4.5132 17.111 +/- 5.6739 P=0.0518 
    Contra lateral 
Pre-op IOP 
   16.758 +/- 3.8582 16.75 +/- 4.7814 P=0.9896 
    
6 weeks 16.198 +/- 5.1798 15.954 +/- 5.3396 P=0.7337 
Contra lateral 
Post op IOP 
3 months 15.657 +/- 4.1674 16.574 +/- 5.4141 P=0.1648 
∆ IOP at 3 mos. 
(mmHg) 
    
 Unadjusted -3.552 +/- 3.6703 -1.492 +/- 4.1139 P<0.0001 
 Adjusted -3.4540  -1.5274 P=0.0020 
∆ IOP at 3 mos. 
(percentage) 
    
 Unadjusted -17.8 +/- 17.804 -7.456 +/- 23.436 P=0.0003 
 Adjusted -17.8835 -7.3684 P=0.0016 
Table 5.  Summary of treatment results.  Change in IOP Adjusted values determined by regression 
analysis.  All values given +/- standard deviation.  Abbreviations: VA, visual acuity, IOP, intra-ocular 
pressure, ∆ IOP, change in intra-ocular pressure. 
 
Pre-operative intra-ocular pressure was statistically equivalent for both treatment arms 
with a mean IOP in the 360° group of 19.299 mmHg and 18.54 mmHg in the 180° group 
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(P=0.1994).  Pre-operative IOPs were also statistically equivalent in the contra lateral, 
untreated eye with measurements of 16.758 mmHg and 16.75 mmHg in the 360° and 180° 
groups, respectively (P=0.9896).  One hour post-operatively, the mean IOP in the 360° group 
was significantly lower than in the 180° group with measurements of 17.028 mmHg and 
19.093 mmHg, respectively (P=0.0158).  At the 6 week and 3 month time points the mean 
IOPs were statistically equivalent (P=0.9285 and P=0.0518, respectively) for both treatment 
arms (see figure 2).   
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Figure 2.  Pressure curves of the treated eyes in the 180° and 360° treatment subgroups including pre-
treatment, one hour, six week and three month measurement values(mmHg).  Pre-treatment values 
were determined by taking the average of intraocular pressure readings from the day of treatment and 
two visits prior to the day of treatment.  The difference in intraocular pressures were only statistically 
significant at the one hour post-treatment time point (P=0.1994, P=0.0158, P=0.9285, P=0.0518).  
Error bars represent the 95% confidence intervals. 
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In the contra lateral, untreated eye the mean IOPs were also statistically equivalent at 
the 6 week and 3 month time points (P=0.7337, P=0.1648, respectively) for both treatment 
arms (see figure 3).   
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Figure 3.  Pressure curves of the eyes contra lateral to the treated eyes in the 180° and 360° treatment 
subgroups including pre-treatment, six week and three month measurement values (mmHg).  Pre-
treatment values were determined by taking the average of intraocular pressure readings from the day of 
treatment and two visits prior to the day of treatment.  There were no statistically significant differences 
in intraocular at any of the time points (P=0.9896, P=0.7337, P=0.1648).  Error bars represent the 95% 
confidence intervals. 
 
While the measured IOPs were equivalent for both treatment arms at the 3 month 
time point, the overall changes in IOP were not.  The baseline-adjusted reduction in IOP for 
the 360° group was 3.552 mmHg and 1.492 mmHg for the 180° group (P<0.0001).  The 
baseline-adjusted reductions in IOP in terms of percentage points were 17.8% and 7.456% in 
the 360° and 180° groups, respectively (P=0.0003).   
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Regression analyses were performed on three month IOP reductions in terms of 
mmHg as well as percent change in order to adjust outcomes for differences in age, overall 
power delivered, gender, type of glaucoma, presence of prior ALT and prostaglandin 
treatment.  In analysis of maximum likelihood estimates, prostaglandins were shown to have a 
significant negative correlation with reduction of IOP (P=0.0305).  The remaining factors were 
not found to have significant correlations with IOP reduction.  After the results were re-
calculated in the regression analyses taking into account these variables, the reduction in IOP 
for the 360° group was 3.4541 mmHg and 1.5274 mmHg for the 180° group (P=0.0020).  The 
adjusted reductions in IOP in terms of percentage points were 17.8834% and 7.3684% in the 
360° and 180° groups, respectively (P=0.0016).   
Two different criteria were established to judge the success of each one of the 
treatment protocols.  One was a greater than 3 mmHg reduction in IOP and the other was a 
greater than 20% reduction in IOP.  The success rates for reduction of IOP greater than 3 
mmHg at one hour were 55 and 25 (P<0.0001) for the 360° and 180° groups, respectively.  At 
6 weeks the rates were equivalent at 57 and 43 (P=0.0561).  At 3 months the 360° group again 
had a significantly better response rate with 65 patients successfully treated compared with 31 
in the 180° group (P<0.0001).   The 360° group had significantly better response rates at all 
three time points for the greater than 20% reduction of IOP criteria.  At the one hour time 
point the success rates were 47 and 18 (P<0.0001), At 6 weeks they were 50 and 32 (P=0.016) 
and at three months they were 55 and 23 (P<0.0001) for the 360° and 180° groups, 
respectively.  The results are graphically represented in figure 4. 
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Table 6 
Treatment Success Rates 
    
1 hour 55 (50.93%) 25 (23.15%) P<0.0001 
6 weeks 57 (52.78%) 43 (39.81%) P=0.0561 
>3mmHg 
Responders 
  
  3 months 65 (60.19%) 31 (28.70%) P<0.0001 
    
1 hour 47 (43.52%) 18 (16.67%) P<0.0001 
6 weeks 50 (46.30%) 32 (29.63%) P=0.016 
>20% 
Responders 
  
3 months 55 (50.93%) 23 (21.30%) P<0.0001 
 
Table 6.  Treatment success rates for both >3mmHg and >20% IOP reduction criteria. 
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Figure 4. Treatment success rates for >3 mmHg reduction in IOP.  The 360° group had 
significantly higher response rates at the 1 hour and three month time points (P>0.0001, P>0.0001) and 
marginally significant at six weeks (P=0.0561). 
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>20% IOP Reduction at 3 months
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Figure 5. Treatment success rates for >20% reduction in IOP.  The 360° group had significantly higher 
response rates at all three time points (P>0.0001, P=0.0160, P>0.0001). 
 
 
Success rates at 3 months for the 3 mmHg criteria, broken down by presence or 
absence of prior prostaglandin treatment and ALT, were also determined.  These results are 
displayed in table 7.  Fifty-nine patients in the 360° group were on prostaglandins with a 
success rate of 33 (55.93%) vs. 23 (26.74) for the 86 of the patients in the 180° group who 
were on prostaglandins.  This was statistically significant (P=0.0004).  Forty-nine patients in 
the 360° group were not on prostaglandins with a success rate of 32 (65.31%) vs. 8 (38.10%) 
of the 21 patients in the 180° group who were not on prostaglandins.  This was statistically 
significant (P=0.0350).   
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Eighteen patients in the 360° group had received prior ALT with a success rate of 9 
(50.00%) vs. 11 (25.58%) of the 43 of the patients in the 180° group that had received prior 
ALT.  This was statistically significant (P=0.0639).  Eighty-eight patients in the 360° group had 
not received prior ALT with a success rate of 56 (63.64%) vs. 20 (30.77%) of the 65 the 
patients in the 180° group who had not received prior ALT.  This was statistically significant 
(P<0.0001). 
Table 7 
Three month SLT success rates (>3mmHg) considering prostaglandin and prior ALT treatment 
Factor  360° 180° Comment 
    w/ Prostaglandins 
Success 33 (55.93%) 23 (26.74%) P=0.0004 
    w/o Prostaglandins 
Success 32 (65.31%) 8 (38.10%) P=0.0350 
Subgroup analysis  P=0.3218 P=0.3039  
    w/ALT 
Success   9 (50.00%) 11 (25.58%) P=0.0639 
    w/o ALT 
Success   56 (63.64%) 20 (30.77%) P<0.0001 
Subgroup analysis  P=0.2791 P=0.5596  
Table 7.  Three month success rates (>3mmHg) considering prostaglandin and prior ALT treatment.  
Subgroup analyses compare success rates of patients on and off prostaglandins or with and without 
prior ALT within treatment groups.  Success rates were not significantly affected in either treatment 
group irrespective of prostaglandins or prior ALT.  Abbreviations: SLT, selective laser trabeculoplasty, 
ALT, argon laser trabeculoplasty. 
 
Subgroup analyses were conducted in order to determine the affect of prostaglandin 
and ALT treatment on success rates for SLT within each of the treatment arms.  In the 360° 
group patients on prostaglandins had a success rate of 55.93% versus a rate of 65.31% for 
those patients not receiving prostaglandins.  This was not a statistically significant difference 
(P=0.3218).  In the 180° group patients on prostaglandins had a success rate of 26.74% versus 
a rate of 38.10% for those patients not receiving prostaglandins.  This was not a statistically 
significant difference (P=0.3039).  In the 360° group patients who had received prior ALT had 
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a success rate of 50.00% versus a rate of 63.64% for those patients who had not.  This was 
not a statistically significant difference (P=0.2791).  In the 180° group patients who had 
received prior ALT had a success rate of 25.58% versus a rate of 74.42% for those patients 
who had not.  This was not a statistically significant difference (P=0.5596).   
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CONCLUSIONS 
Selective laser trabeculoplasty (SLT) is a relatively new treatment technique and the 
optimal amount of power to be deliver and extent of trabecular meshwork to be treated are as 
yet undetermined.  In order to further establish the optimal protocol for treatment of 
glaucoma with SLT we conducted a retrospective chart review of 216 patients.  Of these 216 
subjects 108 received 100 spots over 180° while the other 108 received 100 spots over 360°.  
Our results were similar to the findings of another study conducted by Rinke et al. (66) which 
found a trend towards 360° being more efficacious than 180°.  In that study the 180° degree 
group had a 1.7 mmHg (8.3%) drop in IOP compared with the 1.49 mmHg (8.0%) IOP 
reduction in our study.   In the 360° group there was a 4.5 mmHg (20.7%) drop in IOP in the 
Rinke et al. study while there was a 3.49 mmHg (18%) reduction in our study.  While the trend 
towards 360° being more efficacious did not reach statistical significance in the Rinke et al. 
study, it did in ours.  On the contrary to the Rinke study, another study by Nagar et al. (65) 
found that 360° and 180° of SLT were equally effective.  Despite this, this study still showed 
the significance that different degrees of SLT application can make as they found that both 
180° and 360° were more effective than 90°.  A study by Chen et al. (55) showed that 90° and 
180° of SLT had equivalent efficacies contradicting the significance of degree SLT treated 
found in the above mentioned studies.   
The exact mechanism by which SLT acts is unknown.  All existing hypotheses that 
attempt to describe this mechanism at least partially rely on the biological response to the 
induced expression of cytokines after SLT.  These mechanisms are the increased permeability 
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of the endothelial cells in the TM and Schlemm’s canal (20), remodeling of the extracellular 
matrix of the TM and repopulation of TM endothelial cells (5).  All of these mechanisms 
influence each other and the induction of cytokine expression plays a potential role in 
modulating all of them.  A potentially confounding variable in our study was the fact that the 
180° group received prednisolone post-operatively.  Steroids act by inhibiting phospholipase 
A2 from producing arachidonic acid.  This is the main substrate for both the cyclooxygenase 
and lipooxygenase pathways which are responsible for generating inflammatory cytokines 
thought to be responsible for the biological response to SLT that lowers IOP.  Due to the 
administration of steroids, the 180° group’s response to therapy may have been reduced.  The 
apparent difference in the efficacy between the two groups may, to a certain extent, reflect this 
difference in post-operative treatment rather than the fundamental efficacy of the two 
treatment protocols. 
Another variable that may have affected the outcome between the two groups was the 
density of the energy applied to the TM.   The 180° group had 100 spots applied over one half 
of the TM with a mean total energy of 107.4 mJ.  This was nearly a three fold higher energy 
density than that used in the study conducted by Kramer et al. (2) which described the 
histological changes due to SLT application.  In that study 50 spots were applied over 180° 
with a total energy of about 40 mJ.  The 360° group, on the other hand, received a mean total 
of 45.703 mJ per 180° of TM, which was comparable to the energy delivered in the Kramer 
paper.  In the Kramer study post-treatment scanning electron microscopy showed minimal 
mechanical disruption of the collagen scaffolding and trabecular beams with no evidence of 
crater formation or coagulative damage in the TM.  Transmission electron microscopy found 
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that pigmented TM cells were selectively damaged and killed while leaving adjacent non-
pigmented TM cells unharmed.  While the lack of structural damage to the TM and selective 
damaging of pigmented TM cells can be assumed for the 360° group due to similar SLT 
protocols, this may not have been the case for the 180° group.  This may account for the 
poorer response of patients in the 180° treatment protocol.   
There are other baseline factors that have been documented to affect the outcome of 
SLT.  One of these factors is prostaglandin treatment prior to SLT, which has been shown to 
cause higher failure rate of treatment.  This was reported in a paper by Song et al. although the 
difference in outcomes between those treated and those untreated was not statistically 
significant. In the present study we found a significant inverse relationship between 
prostaglandin treatment and magnitude of IOP reduction.  Despite this, prostaglandin 
treatment did not significantly affect SLT outcomes between the two groups according to the 
two success criteria.  Furthermore, it did not affect the frequency of SLT success within both 
treatment groups during subgroup analyses.  There were a greater number of patients in the 
180° group that were on prostaglandins prior to SLT application.  While this difference existed 
as a potential confounding factor it was not shown to affect the overall outcome when 
considered in the regression analysis.   Baseline IOP and pseudophakic status are two further 
factors that has been shown to affect outcome of SLT (45,50,68,69).  There were not 
statistically significant differences in the baseline IOP or frequency of pseudophakia between 
the two groups so any effect these factors may have had on the outcomes should have been 
equivalent for the two groups.  
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The limits of this study include the fact that it was conducted retrospectively, had a 
brief follow-up period, was conducted by two different surgeons and the increased spot 
density in the 180° group. There were also differences in the amount of patients on 
prostaglandins, with prior ALT, type of glaucoma, gender and ages varied between the two 
groups and total energy was greater in the 180° group.  These factors were all considered when 
conducting the regression analyses and were not found to have a significant effect on 
outcomes.  
In addition to the application of steroids administered post-operatively in one group 
and not the other discussed above, medication regimens in general were managed post-
operatively at the discretion of the performing surgeon.  This leaves the possibility that the 
change in IOP may not have only been effected by application of SLT.  This was unlikely to 
have affected the outcome greatly considering that both groups had a statistically equivalent 
decrease in the number of medication they were taking post operatively.  Another limitation is 
the fact that patients that required an additional application of SLT during the 3 month follow-
up period were not included in analyses.  This precludes the ability to evaluate rates outright 
treatment failure between the two groups. 
The present study suggests that that 360° of SLT is more effective at lowering IOP 
after a three month follow-up period.  This adds to the body of evidence also suggesting that 
greater degrees of SLT treatment are more efficacious.  Further, prospective studies need to be 
conducted in order to elucidate what the optimal degree of treatment is. 
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